| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Stage |
TNM |
Type † |
|
A1 |
1 |
M |
56 |
Esophagus |
Squamous cell carcinoma |
3 |
IIa |
T3N0M0 |
Malignant |
|
A2 |
2 |
M |
63 |
Esophagus |
Squamous cell carcinoma |
3 |
IIa |
T3N0M0 |
Malignant |
|
A3 |
3 |
M |
63 |
Esophagus |
Adenocarcinoma |
3 |
IIa |
T3N0M0 |
Malignant |
|
A4 |
4 |
M |
65 |
Stomach |
Adenocarcinoma (sparse) |
– |
Ib |
T2N0M0 |
Malignant |
|
A5 |
5 |
M |
43 |
Stomach |
Adenocarcinoma |
3 |
IIIa |
T3N1M0 |
Malignant |
|
A6 |
6 |
F |
54 |
Stomach |
Adenocarcinoma |
3 |
IV |
T3N1M0 |
Malignant |
|
A7 |
7 |
M |
70 |
Colon |
Adenocarcinoma |
2 |
III |
T3N1M0 |
Malignant |
|
A8 |
8 |
M |
69 |
Colon |
Adenocarcinoma (chronic inflammation of colon mucosa) |
– |
I |
T2N0M0 |
Malignant |
|
A9 |
9 |
M |
24 |
Colon |
Mucinous adenocarcinoma |
3 |
III |
T3N2M0 |
Malignant |
|
A10 |
10 |
M |
48 |
Rectum |
Adenocarcinoma |
1 |
II |
T4N0M0 |
Malignant |
|
A11 |
11 |
F |
38 |
Rectum |
Adenocarcinoma |
3 |
III |
T3N2M0 |
Malignant |
|
A12 |
12 |
M |
58 |
Rectum |
Adenocarcinoma |
2 |
II |
T4N0M0 |
Malignant |
|
B1 |
13 |
M |
56 |
Esophagus |
Cancer adjacent normal esophagus tissue (skeletal muscle tissue) of No. 1 |
– |
– |
– |
NAT |
|
B2 |
14 |
M |
46 |
Esophagus |
Cancer adjacent normal esophagus tissue |
– |
– |
– |
NAT |
|
B3 |
15 |
M |
64 |
Esophagus |
Cancer adjacent normal esophagus tissue (skeletal muscle tissue) |
– |
– |
– |
NAT |
|
B4 |
16 |
M |
48 |
Stomach |
Cancer adjacent normal stomach tissue |
– |
– |
– |
NAT |
|
B5 |
17 |
M |
43 |
Stomach |
Cancer adjacent normal stomach tissue |
– |
– |
– |
NAT |
|
B6 |
18 |
F |
54 |
Stomach |
Cancer adjacent normal stomach tissue of No. 6 |
– |
– |
– |
NAT |
|
B7 |
19 |
M |
70 |
Colon |
Cancer adjacent normal colon tissue of No. 7 |
– |
– |
– |
NAT |
|
B8 |
20 |
M |
69 |
Colon |
Cancer adjacent normal colon tissue of No. 8 |
– |
– |
– |
NAT |
|
B9 |
21 |
F |
51 |
Colon |
Cancer adjacent normal colon tissue |
– |
– |
– |
NAT |
|
B10 |
22 |
M |
48 |
Rectum |
Cancer adjacent normal rectum tissue of No. 10 |
– |
– |
– |
NAT |
|
B11 |
23 |
F |
38 |
Rectum |
Cancer adjacent normal rectum tissue of No. 11 |
– |
– |
– |
NAT |
|
B12 |
24 |
M |
58 |
Rectum |
Cancer adjacent normal rectum tissue of No. 12 |
– |
– |
– |
NAT |
|
C1 |
25 |
M |
56 |
Liver |
Hepatocellular carcinoma |
2 |
III |
T3N0M0 |
Malignant |
|
C2 |
26 |
M |
39 |
Liver |
Hepatocellular carcinoma |
2 |
II |
T2N0M0 |
Malignant |
|
C3 |
27 |
M |
48 |
Liver |
Hepatocellular carcinoma |
3 |
II |
T2N0M0 |
Malignant |
|
C4 |
28 |
M |
62 |
Lung |
Adenocarcinoma |
3 |
I |
T2N0M0 |
Malignant |
|
C5 |
29 |
M |
39 |
Lung |
Adenocarcinoma |
2 |
I |
T2N0M0 |
Malignant |
|
C6 |
30 |
M |
58 |
Lung |
Squamous cell carcinoma |
2 |
I |
T2N0M0 |
Malignant |
|
C7 |
31 |
F |
60 |
Kidney |
Clear cell carcinoma |
1 |
II |
T2N0M0 |
Malignant |
|
C8 |
32 |
M |
54 |
Kidney |
Clear cell carcinoma |
1 |
I |
T1N0M0 |
Malignant |
|
C9 |
33 |
F |
61 |
Kidney |
Clear cell carcinoma |
1 |
I |
T1N0M0 |
Malignant |
|
C10 |
34 |
F |
51 |
Breast |
Invasive ductal carcinoma |
3 |
IIIb |
T4N2M0 |
Malignant |
|
C11 |
35 |
F |
46 |
Breast |
Invasive ductal carcinoma |
2 |
IIb |
T3N0M0 |
Malignant |
|
C12 |
36 |
F |
52 |
Breast |
Invasive ductal carcinoma |
2 |
IIIb |
T4cN2M0 |
Malignant |
|
D1 |
37 |
M |
31 |
Liver |
Cancer adjacent normal liver tissue |
– |
– |
– |
NAT |
|
D2 |
38 |
M |
61 |
Liver |
Cancer adjacent normal liver tissue |
– |
– |
– |
NAT |
|
D3 |
39 |
M |
48 |
Liver |
Cancer adjacent normal liver tissue (cirrhosis) of No. 27 |
– |
– |
– |
NAT |
|
D4 |
40 |
M |
75 |
Lung |
Cancer adjacent normal lung tissue |
– |
– |
– |
NAT |
|
D5 |
41 |
M |
39 |
Lung |
Cancer adjacent normal lung tissue (hyperplasia of stroma) of No. 29 |
– |
– |
– |
NAT |
|
D6 |
42 |
M |
58 |
Lung |
Cancer adjacent normal lung tissue of No. 30 |
– |
– |
– |
NAT |
|
D7 |
43 |
F |
50 |
Kidney |
Cancer adjacent normal kidney tissue |
– |
– |
– |
NAT |
|
D8 |
44 |
M |
54 |
Kidney |
Cancer adjacent normal kidney tissue of No. 32 |
– |
– |
– |
NAT |
|
D9 |
45 |
F |
61 |
Kidney |
Cancer adjacent normal kidney tissue of No. 33 |
– |
– |
– |
NAT |
|
D10 |
46 |
F |
51 |
Breast |
Cancer adjacent normal breast tissue (fibrous tissue and blood vessel) |
– |
– |
– |
NAT |
|
D11 |
47 |
F |
46 |
Breast |
Cancer adjacent normal breast tissue of No. 35 |
– |
– |
– |
NAT |
|
D12 |
48 |
F |
39 |
Breast |
Cancer adjacent normal breast tissue |
– |
– |
– |
NAT |
|
E1 |
49 |
F |
48 |
Uterine cervix |
Squamous cell carcinoma |
2 |
Ib |
T1bN0M0 |
Malignant |
|
E2 |
50 |
F |
59 |
Uterine cervix |
Squamous cell carcinoma |
2 |
Ib |
T1bN0M0 |
Malignant |
|
E3 |
51 |
F |
32 |
Uterine cervix |
Squamous cell carcinoma |
2 |
IIIa |
T3aN0M0 |
Malignant |
|
E4 |
52 |
F |
48 |
Ovary |
Serous adenocarcinoma |
2 |
I |
T1N0M0 |
Malignant |
|
E5 |
53 |
F |
58 |
Ovary |
Serous adenocarcinoma |
2 |
IIIa |
T3aN0M0 |
Malignant |
|
E6 |
54 |
F |
55 |
Ovary |
Serous adenocarcinoma |
2 |
I |
T1N0M0 |
Malignant |
|
E7 |
55 |
M |
66 |
Bladder |
Transitional cell carcinoma |
2 |
II |
T2N0M0 |
Malignant |
|
E8 |
56 |
M |
42 |
Bladder |
Transitional cell carcinoma |
2 |
II |
T2aN0M0 |
Malignant |
|
E9 |
57 |
M |
76 |
Bladder |
Transitional cell carcinoma |
2 |
II |
T3aN0M0 |
Malignant |
|
E10 |
58 |
M |
36 |
Lymph node |
Diffuse B-cell lymphoma of left groin |
– |
– |
– |
Malignant |
|
E11 |
59 |
M |
15 |
Lymph node |
Diffuse B-cell lymphoma of right submaxillary |
– |
– |
– |
Malignant |
|
E12 |
60 |
M |
39 |
Lymph node |
B-cell lymphoma of right groin |
– |
– |
– |
Malignant |
|
F1 |
61 |
F |
61 |
Uterine cervix |
Cancer adjacent normal uterine cervix tissue |
– |
– |
– |
NAT |
|
F2 |
62 |
F |
35 |
Uterine cervix |
Cancer adjacent normal uterine cervix tissue |
– |
– |
– |
NAT |
|
F3 |
63 |
F |
50 |
Uterine cervix |
Cancer adjacent normal uterine cervix tissue |
– |
– |
– |
NAT |
|
F4 |
64 |
F |
30 |
Ovary |
Cancer adjacent normal ovary tissue |
– |
– |
– |
NAT |
|
F5 |
65 |
F |
39 |
Ovary |
Cancer adjacent normal ovary tissue |
– |
– |
– |
NAT |
|
F6 |
66 |
F |
40 |
Ovary |
Cancer adjacent normal ovary tissue (fibrous tissue and blood vessel) |
– |
– |
– |
NAT |
|
F7 |
67 |
M |
66 |
Bladder |
Cancer adjacent normal bladder tissue of No. 55 |
– |
– |
– |
NAT |
|
F8 |
68 |
M |
42 |
Bladder |
Cancer adjacent normal bladder tissue of No. 56 |
– |
– |
– |
NAT |
|
F9 |
69 |
M |
72 |
Bladder |
Cancer adjacent normal bladder tissue |
– |
– |
– |
NAT |
|
F10 |
70 |
M |
68 |
Lymph node |
Cancer adjacent normal lymph node tissue |
– |
– |
– |
NAT |
|
F11 |
71 |
F |
53 |
Lymph node |
Cancer adjacent normal lymph node tissue |
– |
– |
– |
NAT |
|
F12 |
72 |
M |
69 |
Lymph node |
Cancer adjacent normal lymph node tissue (sparse) |
– |
– |
– |
NAT |
|
G1 |
73 |
F |
84 |
Skin |
Squamous cell carcinoma |
2 |
II |
T2N0M0 |
Malignant |
|
G2 |
74 |
M |
69 |
Skin |
Squamous cell carcinoma |
2 |
II |
T3N0M0 |
Malignant |
|
G3 |
75 |
M |
72 |
Skin |
Squamous cell carcinoma |
3 |
II |
T2N0M0 |
Malignant |
|
G4 |
76 |
M |
18 |
Brain |
Astrocytoma |
2 |
– |
– |
Malignant |
|
G5 |
77 |
F |
43 |
Brain |
Astrocytoma |
2–3 |
– |
– |
Malignant |
|
G6 |
78 |
M |
42 |
Brain |
Astrocytoma |
2–3 |
– |
– |
Malignant |
|
G7 |
79 |
M |
72 |
Prostate |
Adenocarcinoma (hyperplasia) |
– |
II |
T2N0M0 |
Malignant |
|
G8 |
80 |
M |
71 |
Prostate |
Adenocarcinoma (Gleason grade: 1 Gleason score: 1+2) |
1 |
II |
T2N0M0 |
Malignant |
|
G9 |
81 |
M |
76 |
Prostate |
Adenocarcinoma (Gleason grade: 5 Gleason score: 4+5) |
3 |
III |
T3N1M0 |
Malignant |
|
G10 |
82 |
F |
54 |
Pancreas |
Adenocarcinoma |
3 |
– |
– |
Malignant |
|
G11 |
83 |
M |
59 |
Pancreas |
Adenocarcinoma |
3 |
I |
T2N0M0 |
Malignant |
|
G12 |
84 |
M |
73 |
Pancreas |
Undifferentiated carcinoma |
– |
II |
T3N0M0 |
Malignant |
|
H1 |
85 |
M |
64 |
Skin |
Cancer adjacent normal skin tissue |
– |
– |
– |
NAT |
|
H2 |
86 |
M |
69 |
Skin |
Cancer adjacent normal skin tissue of No. 74 |
– |
– |
– |
NAT |
|
H3 |
87 |
F |
61 |
Skin |
Cancer adjacent normal skin tissue |
– |
– |
– |
NAT |
|
H4 |
88 |
M |
68 |
Brain |
Cancer adjacent normal brain tissue |
– |
– |
– |
NAT |
|
H5 |
89 |
M |
59 |
Brain |
Cancer adjacent normal brain tissue |
– |
– |
– |
NAT |
|
H6 |
90 |
F |
58 |
Brain |
Cancer adjacent normal brain tissue |
– |
– |
– |
NAT |
|
H7 |
91 |
M |
35 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
NAT |
|
H8 |
92 |
M |
70 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
NAT |
|
H9 |
93 |
M |
78 |
Prostate |
Cancer adjacent normal prostate tissue |
– |
– |
– |
NAT |
|
H10 |
94 |
M |
44 |
Pancreas |
Cancer adjacent normal pancreas tissue |
– |
– |
– |
NAT |
|
H11 |
95 |
M |
59 |
Pancreas |
Cancer adjacent normal pancreas tissue of No. 83 |
– |
– |
– |
NAT |
|
H12 |
96 |
F |
58 |
Pancreas |
Cancer adjacent normal pancreas tissue |
– |
– |
– |
NAT |
|
–
|
– |
M |
58 |
Skin |
Malignant melanoma (tissue marker) |
– |
|
|
Malignant |
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum